Effect of CL316,243, a highly specific β3-adrenoceptor agonist, on lipolysis of epididymal, mesenteric and subcutaneous adipocytes in rats

Endocrine Journal

Volumn 44, Issue 1, 1997, Pages 181-185

  Umekawa, Tsunekazu ^a   Yoshida, Toshihide ^a   Sakane, Naoki ^a   Kondo, Motoharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Anti obesity drug; Lipolytic action; Visceral fat; White adipose tissue; Adrenoceptor

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLYCEROL; ISOPRENALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SPECIFICITY; EPIDIDYMIS FAT; LIPOLYSIS; MALE; MESENTERY; NONHUMAN; OBESITY; RAT; SUBCUTANEOUS FAT; VISCERA; WHITE ADIPOSE TISSUE;

EID: 0030892216     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.44.181     Document Type: Article

References (31)

1. Arch JRS, Ainsworth AT, Cawthorne MA, Piercy V, Sennit M, Thody V, Wilson C, Wilson S (1984) Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309: 163-165.
2. 3 receptors. A promising antidiabetic and antiobesity agent. J Med Chem 35: 3081-3084.
3. Dolan JA, Muenkel HA, Burns MG, Pellegrino SM, Fraser CM, Pietri F, Strosberg AD, Largis EE, Dutia MD, Bloom JD, Bass AS, Tanikella TK, Cobuzzi A, Lai FM, Claus TH (1994) Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther 269: 1000-1006.
4. 3-adrenoceptor agonist, in yellow KK mice. Life Sci 54: 491-498.
5. 3-adrenoceptor agonist, in mice with monosodium-L-glutamate-induced obesity. Eur J Endocrinol 13: 97-102.
6. 3 and atypical β-adrenoceptors. Med Res Rev 13: 663-729.
7. Lafontan M, Berlan M (1993) Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34: 1057-1091.
8. Kalkhoff RK, Hartz AH, Rupley D, Kissebah AH, Kelber S (1983) Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women. J Lab Clin Med 102: 621-627.
9. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S (1987) Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36: 54-59.
10. Després JP, Nadeau A, Tremblay A, Ferland M, Moorjani S, Lupien PJ, Thériault G, Pinault S, Bouchard C (1989) Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 38: 304-309.
11. Matsuzawa Y, Fujioka S, Tokunaga K, Tarui S (1992) Classification of obesity with respect to morbidity. Proc Soc Exp Biol Med 200: 197-201.
12. Leibel RL, Hirsch J (1987) Site- and sex-related differences in adrenoceptor status of human adipose tissue. J Clin Endocrinol Metab 64: 1205-1210.
13. Fujioka S, Matsuzawa Y, Tokunaga K, Keno Y, Kobatake T, Tarui S (1991) Treatment of visceral fat obesity. Int J Obes 15: 59-65.
14. 3-adrenergic receptor mRNA in man. J Clin Invest 91: 344-349.
15. Wilson C, Wilson S, Piercy V, Sennitt MV, Arch JRS (1984) The rat lipolytic β-adrenoceptor: Studies using novel β-adrenoceptor agonists. Eur J Pharmacol 100: 309-319.
16. Sugasawa T, Matsuzaki M, Morooka S, Foignant N, Blin N (1992) In vitro study of a novel atypical β-adrenoceptor agonist, SM-11044. Eur J Pharmacol 216: 207-215.
17. Rodbell M (1964) Metabolism of isolated fat cells. J Biol Chem 239: 375-380.
18. Eggstein M, Kreutz FH (1996) Eine neue bestimmung der neutralfette im blutserum und gewebe. Klin Wschr 5: 262-267.
19. Fried SK, Lavau M, Pi-Sunyer FX (1982) Variations in glucose metabolism by fat cells from three adipose depots of the rat. Metabolism 31: 876-883.
20. Santos RF, Sztalryd C, Reaven G (1991) Effect of anatomical site on insulin action and insulin receptor phosphorylation in isolated rat adipocytes. Int J Obes 15: 755-762.
21. Hartman AD, Christ DW (1978) Effect of cell size, age and anatomical location on the lipolytic response of adipocytes. Life Sci 22: 1087-1096.
22. Gruen R, Kava R, Greenwood MRC (1980) Development of basal lipolysis and fat cell size in the epididymal fat pad of normal rats. Metabolism 29: 246-253.
23. Hollenga C, Hass M, Deinum JT, Zaagsma J (1990) Discrepancies in lipolytic activities induced by β-adrenoceptor agonists in human and rat adipocytes. Harm Metabol Res. 22: 17-21.
24. Langin D, Portillo MP, Saulnier-Blache JS, Lafontan M (1991) Coexistence of three β-adrenoceptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol 199: 291-301.
25. Simard PM, Atgié C, Mauriège P, D'Allaire F, Bukowiecki LJ (1994) Comparison of the lipolytic effects of norepinephrine and BRL37344 in rat brown and white adipocytes. Obes Res 2: 424-431.
26. Hellmér J, Marcus C, Sonnenfeld T, Arner P (1992) Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab 75: 15-20.
27. Sztalryd C, Kraemer FB (1994) Differences in hormone-sensitive lipase expression in white adipose tissue from various anatomic locations of the rat. Metabolism 43: 241-247.
28. Lönnqvist F, Krief S, Strosberg AD, Nyberg B, Emorine LJ, Arner P (1993) Evidence for a functional β-adrenoceptor in man. Br J Pharmacol 110: 929-936.
29. 3-adrenoceptor in man. J Clin Invest 95: 2239-2245.
30. Hollenga C, Brouwer F, Zaagsma J (1991) Differences in functional cyclic AMP compartments mediating lipolysis by isoprenaline and BRL37344 in four adipocyte types. Eur J Pharmacol 200: 325-330.
31. Van Liefde I, Van Ermen A, Vauquelin G (1994) No functional atypical β-adrenergic receptors in human omental adipocytes. Life Sci 54: 209-214.